Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe

M. Hedberg, Carl Erik Nord, Gebhard Feierl, Maya Marina, Smilja Kalenic, Dittmar Chmelar, Annie Bremmelgaard, Jon Brazier, Hannele Jousimies-Somer, Luc Dubreuil, Alain Lozniewski, Francine Mory, Marina Claros, Eugenia Bezirtzoglou, Zoltan Lajos, E. Nagy, Rossita Todorova, Karl G. Kristinsson, Maria Grazia Menozzi, Hubert EndtzFelicja Meisel-Mikolajczyk, Jana Kolman, Jordi Vila, Connie Jarstrand, Reinhard Zbinden

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objective. To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe. Methods. Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin. Results. There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6% to cefoxitin (64 mg/L), 15% to clindamycin (8 mg/L) and 9% to moxifloxacin (8 mg/L). Less than 1% were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers. Conclusions. Antimicrobial resistance among the B. fragilis group is increasing.

Original languageEnglish
Pages (from-to)475-488
Number of pages14
JournalClinical Microbiology and Infection
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Bacteroides fragilis
beta-Lactamases
Cefoxitin
Clindamycin
Imipenem
Metronidazole
Wound Infection
Ampicillin
Anti-Infective Agents
Agar
Pharmaceutical Preparations

Keywords

  • Antimicrobial resistance
  • Bacteroides fragilis group
  • Beta-lactams
  • Clindamycin
  • Metronidazole
  • Moxifloxacin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Hedberg, M., Nord, C. E., Feierl, G., Marina, M., Kalenic, S., Chmelar, D., ... Zbinden, R. (2003). Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe. Clinical Microbiology and Infection, 9(6), 475-488. https://doi.org/10.1046/j.1469-0691.2003.00674.x

Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe. / Hedberg, M.; Nord, Carl Erik; Feierl, Gebhard; Marina, Maya; Kalenic, Smilja; Chmelar, Dittmar; Bremmelgaard, Annie; Brazier, Jon; Jousimies-Somer, Hannele; Dubreuil, Luc; Lozniewski, Alain; Mory, Francine; Claros, Marina; Bezirtzoglou, Eugenia; Lajos, Zoltan; Nagy, E.; Todorova, Rossita; Kristinsson, Karl G.; Menozzi, Maria Grazia; Endtz, Hubert; Meisel-Mikolajczyk, Felicja; Kolman, Jana; Vila, Jordi; Jarstrand, Connie; Zbinden, Reinhard.

In: Clinical Microbiology and Infection, Vol. 9, No. 6, 01.06.2003, p. 475-488.

Research output: Contribution to journalArticle

Hedberg, M, Nord, CE, Feierl, G, Marina, M, Kalenic, S, Chmelar, D, Bremmelgaard, A, Brazier, J, Jousimies-Somer, H, Dubreuil, L, Lozniewski, A, Mory, F, Claros, M, Bezirtzoglou, E, Lajos, Z, Nagy, E, Todorova, R, Kristinsson, KG, Menozzi, MG, Endtz, H, Meisel-Mikolajczyk, F, Kolman, J, Vila, J, Jarstrand, C & Zbinden, R 2003, 'Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe', Clinical Microbiology and Infection, vol. 9, no. 6, pp. 475-488. https://doi.org/10.1046/j.1469-0691.2003.00674.x
Hedberg, M. ; Nord, Carl Erik ; Feierl, Gebhard ; Marina, Maya ; Kalenic, Smilja ; Chmelar, Dittmar ; Bremmelgaard, Annie ; Brazier, Jon ; Jousimies-Somer, Hannele ; Dubreuil, Luc ; Lozniewski, Alain ; Mory, Francine ; Claros, Marina ; Bezirtzoglou, Eugenia ; Lajos, Zoltan ; Nagy, E. ; Todorova, Rossita ; Kristinsson, Karl G. ; Menozzi, Maria Grazia ; Endtz, Hubert ; Meisel-Mikolajczyk, Felicja ; Kolman, Jana ; Vila, Jordi ; Jarstrand, Connie ; Zbinden, Reinhard. / Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe. In: Clinical Microbiology and Infection. 2003 ; Vol. 9, No. 6. pp. 475-488.
@article{41377babb4b24dd8b87a5b9ee509ff10,
title = "Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe",
abstract = "Objective. To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe. Methods. Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin. Results. There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6{\%} to cefoxitin (64 mg/L), 15{\%} to clindamycin (8 mg/L) and 9{\%} to moxifloxacin (8 mg/L). Less than 1{\%} were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers. Conclusions. Antimicrobial resistance among the B. fragilis group is increasing.",
keywords = "Antimicrobial resistance, Bacteroides fragilis group, Beta-lactams, Clindamycin, Metronidazole, Moxifloxacin",
author = "M. Hedberg and Nord, {Carl Erik} and Gebhard Feierl and Maya Marina and Smilja Kalenic and Dittmar Chmelar and Annie Bremmelgaard and Jon Brazier and Hannele Jousimies-Somer and Luc Dubreuil and Alain Lozniewski and Francine Mory and Marina Claros and Eugenia Bezirtzoglou and Zoltan Lajos and E. Nagy and Rossita Todorova and Kristinsson, {Karl G.} and Menozzi, {Maria Grazia} and Hubert Endtz and Felicja Meisel-Mikolajczyk and Jana Kolman and Jordi Vila and Connie Jarstrand and Reinhard Zbinden",
year = "2003",
month = "6",
day = "1",
doi = "10.1046/j.1469-0691.2003.00674.x",
language = "English",
volume = "9",
pages = "475--488",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Antimicrobial susceptibility of Bacteriodes fragilis group isolates in Europe

AU - Hedberg, M.

AU - Nord, Carl Erik

AU - Feierl, Gebhard

AU - Marina, Maya

AU - Kalenic, Smilja

AU - Chmelar, Dittmar

AU - Bremmelgaard, Annie

AU - Brazier, Jon

AU - Jousimies-Somer, Hannele

AU - Dubreuil, Luc

AU - Lozniewski, Alain

AU - Mory, Francine

AU - Claros, Marina

AU - Bezirtzoglou, Eugenia

AU - Lajos, Zoltan

AU - Nagy, E.

AU - Todorova, Rossita

AU - Kristinsson, Karl G.

AU - Menozzi, Maria Grazia

AU - Endtz, Hubert

AU - Meisel-Mikolajczyk, Felicja

AU - Kolman, Jana

AU - Vila, Jordi

AU - Jarstrand, Connie

AU - Zbinden, Reinhard

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective. To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe. Methods. Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin. Results. There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6% to cefoxitin (64 mg/L), 15% to clindamycin (8 mg/L) and 9% to moxifloxacin (8 mg/L). Less than 1% were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers. Conclusions. Antimicrobial resistance among the B. fragilis group is increasing.

AB - Objective. To evaluate the activity of old and newer antianaerobic drugs against clinical isolates of Bacteroides fragilis group strains from different parts of Europe. Methods. Bacteroides fragilis group isolates from 37 laboratories in 19 countries were biochemically characterized. The MICs of seven antimicrobial agents were determined by the agar dilution method as recommended by the NCCLS. Production of beta-lactamase was detected by nitrocefin. Results. There were 1284 B. fragilis group isolates included in the study. Abdominal infections and wounds were the most common sources of isolation and B. fragilis was the dominating species. Ninety-nine percent of the strains were resistant to ampicillin (breakpoint 2 mg/L), 6% to cefoxitin (64 mg/L), 15% to clindamycin (8 mg/L) and 9% to moxifloxacin (8 mg/L). Less than 1% were resistant to imipenem (16 mg/L), piperacillin-tazobactam (128 mg/L) and metronidazole (32 mg/L). Ninety-six percent of the isolates were beta-lactamase producers. Conclusions. Antimicrobial resistance among the B. fragilis group is increasing.

KW - Antimicrobial resistance

KW - Bacteroides fragilis group

KW - Beta-lactams

KW - Clindamycin

KW - Metronidazole

KW - Moxifloxacin

UR - http://www.scopus.com/inward/record.url?scp=0038004542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038004542&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2003.00674.x

DO - 10.1046/j.1469-0691.2003.00674.x

M3 - Article

C2 - 12848722

AN - SCOPUS:0038004542

VL - 9

SP - 475

EP - 488

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 6

ER -